TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.
TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.
TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.
The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.
TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.
The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.